Opinion EDITORIAL Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts Joshua D. Wallach, MS, PhD; Joseph S. Ross, MD, MHS In December 1993, the US Food and Drug Administration (FDA) potentially providing opportunities to expand postmarket- ing evaluation efforts. Between 1995 and 2004, before com- granted approval for gabapentin, under the brand name Neurontin, for adjunctive therapy of partial seizures. Subse- petition from generic drugs, gabapentin sales increased from quently, the FDA approved $98 million to nearly $3 billion per year. During this time, gabapentin in 2000 for treat- gabapentin was used to treat conditions as varying as fibro- ment of partial seizures in myalgia and other chronic pain syndromes, psychiatric disor- Related article page 818 children aged 3 years or older ders, and migraine headaches, all off-label uses at the discre- and in 2002 for treatment of postherpetic neuralgia. How- tion of physicians that have not been formally approved ever, over the past 25 years, gabapentin has been prescribed by the FDA. By 2000, gabapentin was the top-selling anticon- for a variety of indications beyond those formally evaluated vulsant and ranked 17th for total expenditures among by the FDA. all drugs. In this issue of JAMA,Mooreetal
JAMA – American Medical Association
Published: Feb 27, 2018
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera